tradingkey.logo
tradingkey.logo

enVVeno Medical Corp

NVNO
10.380USD
-0.130-1.24%
Market hours ETQuotes delayed by 15 min
4.67MMarket Cap
LossP/E TTM

enVVeno Medical Corp

10.380
-0.130-1.24%

More Details of enVVeno Medical Corp Company

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

enVVeno Medical Corp Info

Ticker SymbolNVNO
Company nameenVVeno Medical Corp
IPO dateMay 31, 2018
CEOBerman (Robert A)
Number of employees37
Security typeOrdinary Share
Fiscal year-endMay 31
Address70 Doppler
CityIRVINE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92618
Phone19492612900
Websitehttps://envveno.com/
Ticker SymbolNVNO
IPO dateMay 31, 2018
CEOBerman (Robert A)

Company Executives of enVVeno Medical Corp

Name
Name/Position
Position
Shareholding
Change
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.50K
-5.59%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
319.00
+7.21%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
265.00
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
46.00
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.50K
-5.59%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
319.00
+7.21%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
265.00
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
46.00
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Wed, Feb 25
Updated: Wed, Feb 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Satterfield (Thomas A Jr)
7.94%
Perceptive Advisors LLC
7.67%
Kingdon Capital Management, L.L.C.
5.52%
CM Management, LLC
5.45%
Northstrive Fund II LP
3.07%
Other
70.35%
Shareholders
Shareholders
Proportion
Satterfield (Thomas A Jr)
7.94%
Perceptive Advisors LLC
7.67%
Kingdon Capital Management, L.L.C.
5.52%
CM Management, LLC
5.45%
Northstrive Fund II LP
3.07%
Other
70.35%
Shareholder Types
Shareholders
Proportion
Individual Investor
11.45%
Investment Advisor
8.61%
Hedge Fund
8.33%
Private Equity
7.67%
Corporation
3.07%
Research Firm
2.33%
Investment Advisor/Hedge Fund
1.42%
Venture Capital
0.29%
Other
56.83%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
80
175.24K
26.73%
-63.76K
2025Q3
76
5.69M
28.14%
-667.58K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Satterfield (Thomas A Jr)
1.82M
9.02%
+1.82M
--
Nov 14, 2025
Perceptive Advisors LLC
1.76M
8.7%
+474.07K
+36.89%
Sep 30, 2025
Kingdon Capital Management, L.L.C.
1.36M
6.72%
+500.00K
+58.19%
Sep 30, 2025
CM Management, LLC
600.00K
2.97%
+600.00K
--
Sep 30, 2025
The Vanguard Group, Inc.
861.19K
4.26%
+162.85K
+23.32%
Sep 30, 2025
Berman (Robert Andrew)
222.24K
1.1%
+200.00K
+899.44%
Oct 17, 2025
Geode Capital Management, L.L.C.
201.24K
1%
+1.74K
+0.87%
Sep 30, 2025
View more

Related ETFs

Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Jan 15, 2026
Merger
35→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Date
Ex-dividend Date
Type
Ratio
Jan 15, 2026
Merger
35→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
KeyAI